---
title: "Nonoperative Management of Esophageal Cancer"
editor: visual
bibliography: zotero.bib
---

# Non-operative management of esophageal cancer

Interval between neoadjuvant therapy and surgery

NeoRES trial: [@nilsson1015] randomized trial: worse outcome with longer interval

DUA observational [@wang808]: worse outcome with longer interval

But neoadjuvant FLOT indocued 27% pCR in the DNATE study [@lorenzen410] Lorenzen S, Götze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 Trial. J Clin Oncol 2024; 42: 410–20.

an T, Zhang X-F, Liang C, Liao C-W, Li J-Y, Zhou Y-M. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies. Ann Surg Oncol 2019; 26: 1412–20.

Bite on Bite Biopsies (PreSANO) Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 2018; 19: 965–74.

Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Dis Esophagus 2017; 30: 1–8.
